The trial attained each its Main endpoints, with semaglutide 2.4 mg demonstrating statistically major and outstanding enhancements in liver fibrosis with no worsening of steatohepatitis, and resolution of steatohepatitis with no worsening of liver fibrosis in those with MASH in comparison with placebo.1Semaglutide is available in a powder kind and … Read More